C Merry. Show Affiliations »
Abstract
Entities: Chemical Disease Species
Mesh: See more » Aryl Hydrocarbon HydroxylasesCytochrome P-450 CYP2C19Cytochrome P-450 CYP3ACytochrome P-450 Enzyme InhibitorsCytochrome P-450 Enzyme System/biosynthesisCytochrome P-450 Enzyme System/metabolismDrug InteractionsDrug MonitoringDrug Therapy, CombinationEnzyme Inhibitors/therapeutic useHIV Infections/drug therapyHIV Protease Inhibitors/bloodHIV Protease Inhibitors/metabolismHIV Protease Inhibitors/therapeutic useHumansMixed Function Oxygenases/antagonists & inhibitorsMixed Function Oxygenases/biosynthesisMixed Function Oxygenases/metabolismNelfinavir/bloodNelfinavir/metabolismNelfinavir/therapeutic useOmeprazole/therapeutic use
Substances: See more » Cytochrome P-450 Enzyme InhibitorsEnzyme InhibitorsHIV Protease InhibitorsCytochrome P-450 Enzyme SystemMixed Function OxygenasesAryl Hydrocarbon HydroxylasesCYP2C19 protein, humanCYP3A protein, humanCytochrome P-450 CYP2C19Cytochrome P-450 CYP3ANelfinavirOmeprazole
Year: 2001 PMID: 11399989 DOI: 10.1097/00002030-200105250-00015
Source DB: PubMed Journal: AIDS ISSN: 0269-9370 Impact factor: 4.177